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Complement Factor H (CFH), with 20 short complement regulator (SCR) domains,
regulates the alternative pathway of complement in part through the interaction of its C-
terminal SCR-19 and SCR-20 domains with host cell-bound C3b and anionic
oligosaccharides. In solution, CFH forms small amounts of oligomers, with one of its
self-association sites being in the SCR-16/20 domains. In order to correlate CFH function
with dimer formation and the occurrence of rare disease-associated variants in SCR-16/
20, we identified the dimerization site in SCR-16/20. For this, we expressed, in Pichia
pastoris, the five domains in SCR-16/20 and six fragments of this with one-three domains
(SCR-19/20, SCR-18/20, SCR-17/18, SCR-16/18, SCR-17 and SCR-18). Size-exclusion
chromatography suggested that SCR dimer formation occurred in several fragments.
Dimer formation was clarified using analytical ultracentrifugation, where quantitative c(s)
size distribution analyses showed that SCR-19/20 was monomeric, SCR-18/20 was
slightly dimeric, SCR-16/20, SCR-16/18 and SCR-18 showed more dimer formation, and
SCR-17 and SCR-17/18 were primarily dimeric with dissociation constants of ~5 µM. The
combination of these results located the SCR-16/20 dimerization site at SCR-17 and
SCR-18. X-ray solution scattering experiments and molecular modelling fits confirmed the
dimer site to be at SCR-17/18, this dimer being a side-by-side association of the two
domains. We propose that the self-association of CFH at SCR-17/18 enables higher
concentrations of CFH to be achieved when SCR-19/20 are bound to host cell surfaces in
order to protect these better during inflammation. Dimer formation at SCR-17/18 clarified
the association of genetic variants throughout SCR-16/20 with renal disease.
Keywords: analytical ultracentrifugation, complement factor H, inflammation, molecular modelling,
X-ray scatteringorg January 2021 | Volume 11 | Article 6018951
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The complement system is an enzymatic cascade in the innate
immunity which acts against damaged cells or invading pathogens
before they can cause infection. In the alternative pathway of
complement activation, non-active complement C3 is
spontaneously hydrolyzed in a tickover mechanism to C3u [also
known as C3(H2O)], which is conformationally similar to active
C3b. C3u leads to the amplification of C3 cleavage through the C3
convertase, which now hydrolyses C3 to form active C3b. C3b
binds to exposed cell surfaces, targeting them for immune
destruction. Complement Factor H (CFH) prevents complement-
mediated host cell destruction through the interaction of its C-
terminus with surface-bound C3b on anionic host cell surfaces (1,
2). Thus CFH acts as a cofactor for Factor I which cleaves C3b to
inactive iC3b (3).
CFH is a 154 kDa glycoprotein composed of 20 short
complement regulator (SCR) domains, each containing
approximately 61 amino acids, and linked to each other by
three to eight amino acids (Figure 1A) (4). There are nine N-
linked glycosylation sites of which eight are occupied (5).
Molecular structure determination for full length CFH is
difficult due to its size, glycosylation, interdomain flexibility,
and self-association. Nonetheless, high resolution structures are
available for 12 SCR domain fragments of CFH solved by X-ray
crystallography and for seven SCR domains solved by NMR
spectroscopy (6). This leaves SCR-9, SCR-14 and SCR-17 as the
only domains without high resolution structures (Figure 1A);
however molecular models of these are available through
standard homology modelling. Early electron microscopy and
small angle scattering methods showed that full length CFH
possesses a folded-back SCR domain structure through either its
N- or C- terminals (6–8). The CFH C-terminal SCR-19 and SCR-
20 domains in SCR-19/20 interact with C3b and its thioester
domain C3d (9, 10). SCR-20 interacts with the cell surface
through anionic interactions (11). Furthermore, CFH self-
associates weakly, and that CFH forms dimers alongside higher
oligomers that are directly observed as distinct peaks by
analytical ultracentrifugation (AUC) (12). One of the two CFH
self-association sites is localized to the five-domain fragment
SCR-16/20 which exists in a monomer-dimer equilibrium, as
shown using both AUC and small angle X-ray scattering (SAXS),
although it was unclear from that study where the dimerization
site was located in SCR-16/20 (13).
Atypical hemolytic uremic syndrome (aHUS) is a rare disease
which is characterized by damage to the endothelial cells of the
kidney through impaired complement regulation. It leads to end-
stage renal failure and is often fatal (14). aHUS has been strongly
associated with mutations in CFH (15–17). CFH-associated
genetic variants cause loss of function which impairs the
protection of the endothelial surfaces of the kidney, and causes
complement activation on these surfaces (18). The most recent
survey of CFH variants reported that there were 190 disease-Abbreviations: C3, complement component 3; CFH, Factor H; SCR, short
complement regulator.
Frontiers in Immunology | www.frontiersin.org 2associated variants in CFH (17, 19). Of these, 83 were located in
the five C-terminal SCR domains of CFH. The web database
(https://www.complement-db.org/) currently indicates six
variants in SCR-16, four in SCR-17, ten in SCR-18, seven in
SCR-19 and 37 in SCR-20 (Figures 1B, C). The majority of
these variants are located in SCR-20 which has binding sites
for C3b, C3d and anionic surfaces, demonstrating that
these variants will directly perturb the ability of CFH to
recognize and protect host cells. A further group of CFH
variants involves 29 of the 40 disulphide bridges in CFH in
which a single Cys residue is replaced, meaning that disease
would be caused by protein misfolding of the SCR domain in
question and the destabilisation of the CFH protein structure
(19). Other complement-associated renal diseases include C3
glomerulopathy (C3G) (17).
In order to identify the CFH self-association site in
SCR-16/20 and to clarify the involvement of the aHUS-
associated variants in SCR-16/20 on the protein structure, we
expressed seven recombinant fragments of these five C-terminal
SCR domains. Using a combination of size exclusion
chromatography, AUC and SAXS in both 137mM NaCl
(physiological salt) and 50 mM NaCl (low salt) buffers, we
identified the C-terminal dimer site in CFH to be within the
double-domain SCR-17/18 region. From our AUC and SAXS
results we propose that the dimer is formed by a side-by-side
association of the SCR-17/18 domains, and confirmed this by
recourse to recently-modelled solution structures for full-length
CFH (6). We discuss the implications of our self-association
results for CFH function and how genetic variants may
compromise the function of CFH.MATERIALS AND METHODS
Expression and Purification of the
CFH Fragments
In order to locate the self-association site in the SCR-16/20
region of CFH, between one to five domains in the SCR-19/20,
SCR-16/20, SCR-18/20, SCR-16/18H, SCR-17/18H, SCR-17H,
and SCR-18H constructs were expressed and purified for this
study, where the suffix H indicated the presence of a His tag (13).
The N- and C-terminal sequences of the expressed SCR domains
depended on the fragment. For all seven SCR fragments, the N-
termini contain the sequence EAEAF corresponding to the a-
factor secretion signal and the EcoRI restriction enzyme site.
The SCR-18H, SCR-17H, SCR-17/18H, and SCR-16/18H
C-termini contain the first four amino acids of the next linker
region followed by the myc tag and His tag sequences
ALEQKLISEEDLNSAVDHHHHHH (Figure 1C). The SCR-
16/18 and SCR-16/20 fragments contained the last three
residues while the SCR-19/20 fragment contained the last four
residues of the linker at its N-terminal. The SCR domains were
cloned into the Pichia pastoris expression plasmid pPICZaA and
transformed into wild-type X33 cells. Expression was carried out
according to Invitrogen guidelines. Briefly, transformants were
selected using zeocin given that pPICZaA encodes a zeocinJanuary 2021 | Volume 11 | Article 601895
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2% glycerol for four days. Recombinant protein expression was
induced using 0.5% methanol and was maintained every 24 h for
four days. Cells were removed by centrifugation and the
supernatant containing the secreted SCR domains were
concentrated using a 5 kDa molecular weight cutoff membrane.
Fragments with the C-terminal hexa-histidine tags were
purified using a 5 ml HiTrap Nickel column (GE Healthcare).
The supernatant was dialyzed against 50 mMNaH2PO4, 300 mM
NaCl, 10 mM imidazole, pH 8.0 (wash buffer), and loaded onto
the column using an AKTA purifier system (GE Healthcare)
which had been equilibrated with wash buffer. The column was
washed with five column volumes of wash buffer to remove any
non-specifically bound protein. Protein was eluted using 50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0. For the
non-His-tagged SCR domains, ion exchange chromatography
was used. SCR-19/20, SCR-16/20 and SCR-18/20 have
theoretical isoelectric points of 9.05, 8.04 and 7.69 respectively,
thus cation exchange chromatography was used. The
supernatant was dialyzed against 50 mM Tris-HCl pH 7.4, 25
mM NaCl, 1 mM EDTA and loaded onto a SP FF column (GE
Healthcare) which had been pre-equilibrated with the same
buffer. After loading, the column was washed with five column
volumes of buffer. Protein was eluted using a salt gradient up to 1
MNaCl. In all seven purifications, protein elution was monitoredFrontiers in Immunology | www.frontiersin.org 3using the absorbance at 280 nm. Fractions were pooled and
concentrated using Amicon ultra centrifugal filters with a
molecular weight cutoff membrane of 10 kDa or 3 kDa
depending on the SCR domain. Size exclusion chromatography
removed any remaining impurities and aggregation (Figure 2A).
Protein samples were injected onto a Superdex 75 (GE
Healthcare) column which had been equilibrated with 10 mM
Hepes, 137 mM NaCl, pH 7.4. Molecular weight standards were
from BioRad (BioRad Gel Filtration Standard, Hertfordshire,
UK). SDS-PAGE monitored sample purity (Figure 2B).
Analytical Ultracentrifugation of
the CFH Fragments
Analytical ultracentrifugation (AUC) data were collected for
each SCR fragment in two buffers, namely 10 mM Hepes pH
7.4, 137 mM NaCl and 10 mM Hepes pH 7.4, 50 mM NaCl.
Experiments were carried out in two sector cells (buffer and
sample) with column heights of 12 mm. Data were collected in a
concentration series between 0.2 – 3 mg/ml for each fragment.
Sedimentation velocity experiments were carried out at 20 °C
using an AnTi50 rotor at 50,000 rpm in a Beckman-Coulter
Proteome XL-I analytical ultracentrifuge. Interference and
absorbance optics at 280 nm were used for detection
depending on concentrations, the absorbance data being
saturated at higher concentrations. Size distribution c(s)A
B
C
FIGURE 1 | Domain structure and sequences for the Factor H C-terminal domains. (A) Schematic diagram of the 20 SCR domains in Factor H, showing their
functional significance, knowledge of their protein structures, and their glycan chains. (B) Schematic view of the SCR-15/16 protein structures with their disease-
associated mutations as blue spheres (aHUS), green spheres (aHUS and C3G) and yellow spheres (C3G). The number of mutations in each domain is bracketed
beside the domain label. (C) The five domain sequences are shown, with the five conserved Trp and Cys residues highlighted in black, and other conserved residues
in yellow. The two glycosylation sites are underlined. The inter-SCR linkers are boxed. Residues highlighted in grey have b-strand secondary structures. The disease-
associated residues are colored in red. If expressed with a hexaHis tag, the C-terminal sequence in green will be present. The N-terminal sequence EAEAEF is the a-
factor signal and the EcoRI site.January 2021 | Volume 11 | Article 601895
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B
FIGURE 2 | Protein purifications for seven C-terminal domains of Factor H. (A) Size exclusion chromatography elution profiles of each of the seven SCR fragments.
The molecular mass of the calibration standards are shown in full for SCR-19/20 and in part for the others. The assignment of the peaks as monomer or dimer is
denoted by M and D respectively. (B) SDS-PAGE analysis of each of the seven SCR fragments. Lanes 1 and 2, SCR-19/20 non-reduced and reduced respectively;
lanes 3 and 4, SCR-18/20 non-reduced and reduced; lanes 5 and 6, SCR-16/20 non-reduced and reduced; lanes 7 and 8, SCR-16/18H non-reduced and reduced;
lanes 9 and 10, SCR-17/18H non-reduced and reduced; lanes 11 and 12, SCR-18H non-reduced and reduced; lanes 13 and 14, SCR-17H non-reduced; and
reduced. Molecular weight standards in kDa are shown to the left.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6018954
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SEDFIT according to the Lamm equation (version 14.6) to give
the sedimentation coefficients s which were corrected to standard
s20,w values to allow for the density of water and 20°C (20, 21).
Totals of 80-100 boundaries were used with the frictional ratio
(f/f0), meniscus and baseline all floated in the final analyses. The
c(s) plots were converted to molar mass distribution c(M) in
order to assess the molecular mass of each sedimenting species.
Small Angle X-Ray Scattering of
the CFH Fragments
Small angle X-ray scattering (SAXS) experiments were
performed on each of the SCR domains in both 10 mM Hepes,
137 mM NaCl, pH 7.4, and 10 mM Hepes, 50 mM NaCl, pH 7.4
buffers between concentrations of 0.5–2 mg/ml. Data were
collected on the bioSAXS beamline BM29 at the European
Synchrotron Radiation Facility, Grenoble, France (22). The X-
ray wavelength was 0.09919 nm. All experiments were carried
out at 20°C. An automated capillary flow sample changer was
used on BM29 in which the buffer backgrounds were measured
before and after each protein sample (23). Sample volumes of
50 ml were used, collecting 10 frames at a rate of one frame per
second. Frames that showed no radiation damage or aggregation
were averaged, and the averaged buffer frames were subtracted
from the protein scattering curves. EDNA software provided
automatic data processing in which the intensities I(Q) were
automatically scaled by concentration (24). The Biosaxs
Customized Beamline Environment (BsxCuBE) software was
used for control of the automatic sample changer, and the
sample settings were loaded from the Information System for
Protein Crystallography Beamlines database (ISPyB) (22, 25).
Guinier analyses at low Q (where Q = 4p sin q/l; 2q is the
scattering angle and l is the wavelength) were then performed
according to the Guinier equation (26).
ln I(Q) = ln I(0)RG2Q2=3
Initial data subtraction and Guinier analyses were carried out
using the software Primus (27). The radius of gyration RG was
calculated, which monitors the overall elongation of the protein
in a given solute-solvent contrast if the internal inhomogeneity of
scattering densities within the glycoprotein has no effect. The RG
value was calculated from the linear portion of the Guinier plot
(ln I(Q) vQ2) within an upperQ.RG limit of 1.5, together with the
forward scattering intensity at zero angle I(0). The program
GNOM was used to transform the scattering curves in reciprocal
space (I(Q)) into real space via an indirect Fourier transform to






I Qð ÞQr sin Qrð ÞdQ
The P(r) curve corresponds to the distribution of distances r
between volume elements in the molecule. The P(r) curve yields
the RG value in real space together with L, the maximum
dimension of the molecule, and M, the most frequently
observed interatomic distance in the molecule.Frontiers in Immunology | www.frontiersin.org 5Molecular Modelling of the Seven
CFH Fragments
The most recent scattering modelling of the 20 SCR domains in
CFH used a combination of MODELLER v9.14 and monomer
Monte Carlo (SASSIE-web) (91) to build a starting CFH model
from previously-known NMR and crystal structures for 17 SCR
domains and three SCR homology models for SCR-9, SCR-14
and SCR-17 (6, 29, 30). Eight biantennary disialylated glycans
were added to this CFH model (5). In four Monte Carlo
simulations based on conformationally varying the inter-SCR
linkers, 510,000 full-length CFH models were created, of which
many were discarded for reason of steric clashes between the
SCR domains to result in a library of 29,715 physically-realistic
CFH models for SAXS curve fitting (6). A theoretical scattering
curve was generated from each model for comparison with the







where Qi is the Q value of the i-th data point, Iexp(Qi) is the
experimental scattering intensity and Imodel(Qi) is the theoretical
modelled scattering intensity. The R-factor vs RG graphs for
29,715 CFH models were filtered on both the RG value and R-
factor. The best-fit 100 models were identified by ranking the
filtered models by their R-factors. The Tyr402His polymorphism
had no effect on the curve fits, leading to an R-factor difference of
only 0.0003%, thus only the Tyr402 CFH models were used in
the present study. These best-fit models are available from the
Supplementary Materials of our earlier study (6); they are not
available in the small angle scattering biological data bank
(SASBDB) because this data bank is not suited to the
deposition of atomistic scattering models.
In order to evaluate whether the seven CFH fragments of this
study could be fitted to monomer models for their structures, each
of the 100 best fit CFH Tyr402 models were edited to generate
their seven fragments. Those for SCR-19/20, SCR-18/20 and SCR-
16/20 were unchanged from those found in the full-length CFH
models. Those for SCR-16/18H, SCR-17/18H, SCR-18H, and
SCR-17H were modified by the addition of the C-terminal
Histag sequence ALEQKLISEEDLNSAVDHHHHHH to the
SCR models edited from the full-length CFH models (Figure
1C). This additional structure was added to each SCR fragment
using MODELLER version 9.14. Because MODELLER does not
handle glycans, the two biantennary disialylated glycan chains
were reinstated on SCR-17 and SCR-18 by superimpositions
using PyMol. CHARMM-GUI software was used to generate
the CHARMM force field and PSF inputs for energy
minimization in SASSIE-web (6). Once the two glycans were
added to the SCR model and accepted by GlycanReader, bash
scripts were used to finalize the nomenclature and numbering
of the glycan and protein atoms in order to match the
experimental protein.
For the AUC modelling, the theoretical s°20,w values for the
seven FH fragments were calculated directly from the atomic
coordinates with the default value of 0.31 nm for the atomicJanuary 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor Helement radius for all atoms to represent the hydration shell by
using the HYDROPRO shell modelling program (32, 33).
The sequence alignment of CFH SCR-17/18 with the SCR-1/2
domains of complement Factor H related-1 protein (FHR1) was
carried out for the Uniprot KB sequences using the EMBOSS
water sequence pairwise alignment tool (34). The SCR-17/18
domains were structurally aligned with the FHR1 SCR-1/2
domains using PyMol. This used the homology model for
SCR-17 from the solution structure of CFH SCR-16/20 (13),
SCR-18 from the crystal structure of CFH SCR-18/20 (35) and
the crystal structure of the FHR1 SCR-1/2 dimer (PDB code:
3ZD2) (36). Alignment was carried out using the core residues of
the b4 strand of each SCR domain, where SCR-17 was aligned
with SCR-1, and SCR-18 was aligned with SCR-2.RESULTS
Purification of the Seven SCR
Fragments of CFH
The non-tagged SCR-19/20, SCR-18/20 and SCR-16/20
fragments were successfully purified from the P. pastoris
growth media supernatant by cation exchange chromatography
(13). Size exclusion chromatography, which separates molecules
based on their size and shape, was used as the final purification
step. Molecular weight standards were used to estimate the
molecular weight, and therefore oligomeric state, of each of the
SCR fragments. Elution was monitored by absorbance at 280 nm
(Figure 2A). SCR-19/20 eluted as a single symmetrical peak with
an apparent mass of 10 kDa, which is comparable to 14.7 kDa
expected for the monomer (M). Both SCR-18/20 and SCR-16/20
eluted with a single broad peak with a small shoulder peak on the
left. SCR-18/20 showed an estimated mass of 77 kDa, and SCR-
16/20 showed a mass of 71 kDa, both of which were much larger
than the expected masses of 24 kDa and 38 kDa respectively. The
discrepancies between the observed and expected molecular
masses were attributed to the elongated shapes of the three
fragments, in distinction to the molecular weight standards used
for the column calibrations which were a set of globular proteins
of compact shapes.
Four additional fragments containing one-to-three domains
and His-tagged C-termini, namely SCR-16/18H, SCR-17/18H,
SCR-17H, and SCR-18H, were likewise purified from the yeast
supernatant using nickel affinity chromatography. SCR-16/18H,
SCR-17/18H, SCR-18H, and SCR-17H eluted with two
overlapping peaks that were assigned to dimer (D) and
monomer (M) (Figure 2A). SCR-16/18H, SCR-17/18H, and
SCR-17H showed more dimer than monomer, while SCR-18H
showed more monomer. For SCR-16/18H, even though the
predicted mass from the sequence was 29 kDa, peaks D and M
showed masses of 141 kDa and 120 kDa respectively. For SCR-
17/18H, even though the predicted mass from the sequence was
22 kDa, peaks D and M showed masses of 102 kDa and 84 kDa
respectively. SCR-17H with a predicted mass of 10 kDa showed
apparent molecular masses of 48 kDa and 23 kDa for peaks D
and M respectively. SCR-18H with a predicted mass of 11 kDaFrontiers in Immunology | www.frontiersin.org 6showed apparent molecular masses of 79 kDa and 48 kDa for
peaks D and M respectively. The discrepancies between the
observed and expected molecular masses in the latter cases
were attributed to the presence of both glycan chains and
extended His-tag structures.
Protein purities were assessed by SDS-PAGE (Figure 2B). As
SCR-17 and SCR-18 contained N-linked glycan chains, six of the
SCR fragments (Figure 1B) showed streaking on the gel which is
characteristic of glycosylated proteins, and seen previously for SCR-
16/20 (13). SDS does not bind sufficiently to glycan chains, resulting
in a non-uniform net charge in SDS-PAGE. As expected, only SCR-
19/20 showed one band. Multiple bands were observed for the
glycosylated fragments and attributed to variations in the
glycosylation pattern which is often observed for glycoproteins
expressed in P. pastoris (37). The purity and consequently the
identity of each of the constructs used in this study was confirmed
by Western blots using an anti-FH polyclonal goat antibody. With
the exception of SCR-18, all bands that were present on the SDS-
PAGE gel were confirmed to be FH. For SCR-18, MALDI-TOF
mass spectroscopy analysis was carried out to confirm its mass as
11,180 Da, in agreement with the sequence.Mass variations of ± 700
Da were observed corresponding to the differential glycosylation
pattern in SCR-18.
AUC of the Seven CFH Fragments
in 137 mM NaCl
AUC quantitatively separates macromolecules according to their
size and shape, this method being superior to the qualitative
estimates from size-exclusion chromatography (38). Different
molecular species within a sample are detected from the peaks in
the size distribution c(s) analyses (Figure 3, right) that are
calculated from the sedimentation boundaries (Figure 3, left).
The sedimentation coefficient s20,w at 20°C and corrected for the
density of water gives the frictional ratio f/fo. This measures the
protein shape, with a compact globular protein typically having a
f/fo ratio of 1.2 where f is the observed frictional coefficient and f0
is the frictional coefficient for a spherical protein with the same
mass. The f/fo ratio will indicate the degree of elongation upon
protein dimerization. The relative percentages of monomer and
dimer in the sample are calculated from peak integrations in the
c(s) analyses. These integrations give the dissociation constant
KD for dimer formation. Conversion of the c(s) peaks to the
corresponding mass distributions c(M) gives the molecular mass
for each species present.
Interference optics were used for the three non-His tagged
fragments SCR-19/20, SCR-18/20 and SCR-16/20, where good
boundary fits were obtained in all cases (Figure 3A). For this
work, buffers with 137 mM NaCl were used that correspond
closely to the ionic strength of blood plasma.
(i) For SCR-19/20, only one peak was visible in the c(s) plot
for four concentrations, indicating that only monomer was
present with an s20,w value of 1.6 S (Figure 4). The c(M)
analysis gave a molecular mass of 15–18 kDa, which was in
good agreement with the sequence-calculated mass of 15 kDa.
The f/fo ratio for SCR-19/20 was 1.1 showing that it had a
relatively compact shape (Table 1).January 2021 | Volume 11 | Article 601895
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value of 2.4 S corresponding to the monomeric protein. At higher
concentrations of 2–3 mg/ml, a small shoulder peak was evident
with an s20,w of 3.1 S which was attributed to a low amount of
dimer formation (Figure 3A). Integration showed that this
shoulder peak accounted for 10–18% of the sample for 2–3
mg/ml (Figure 4B). From this, the dissociation constant KD for
the SCR-18/20 dimer was estimated to be 590 ± 150 µM. The
molecular mass for the monomer was determined to be 26–34
kDa, in accord with the sequence-calculated monomer mass of
24 kDa, and 58 kDa for the shoulder peak to confirm that this
was dimer. SCR-18/20 showed a f/f0 ratio of 1.1 for the monomer
and 1.6 for the dimer peak, showing that the dimer was more
elongated than the monomer (Table 1).
(iii) The c(s) curve for SCR-16/20 showed the presence of
monomer and dimer with two partially merged peaks
corresponding to a monomer-dimer equilibrium, with the
monomer s20,w value at 2.6 S and the dimer s20,w value at 3.6 S
(Figure 3A), as reported previously (13). The 60–40% ratio of
monomer-dimer did not significantly change with concentration
(Figure 4B), and resulted in a KD value of 31 ± 14 µM for dimerFrontiers in Immunology | www.frontiersin.org 7formation. The molecular masses were determined to be 41–48
kDa for the monomer and 65–66 kDa for dimeric SCR-16/20, as
expected from the sequence-calculated monomer mass of 38
kDa. The f/f0 ratio was 1.5 for the monomer and 1.7 for the
dimer, indicating that the dimer was slightly more elongated
than the monomeric protein (Table 1).
In order to locate the dimerization site more precisely, four
His-tagged SCR fragments were available, based on SCR-16,
SCR-17, and SCR-18, and denoted by H suffixes. AUC data for
these were based on both interference and absorbance optics for
which again good boundary fits were obtained (Figures 3B–E):
(iv) For SCR-16/18H, the c(s) plots showed well-resolved
monomer and dimer peaks, even at low concentrations of 0.2
mg/ml (Figure 3B). Interference optics gave s20,w values of 2.6 S
and 2.3 S for the monomer and 4.0 S and 3.6 S for the dimer.
Absorbance optics gave s20,w values of 2.5 S and 3.6 S for the
monomer and dimer respectively. The c(M) analyses gave 21–32
kDa for the monomer and 40–55 kDa for the dimer, in good
accord with the sequence-calculated monomer mass of 29 kDa.
Integration showed that SCR-16/18H was 40% monomer and





FIGURE 3 | Sedimentation velocity c(s) distribution analyses of the C-terminal SCR fragments. In the left panels, 60–80 scans and boundary fits are shown using
interference optics. Only every seventh to tenth scan is shown. In the right panels, the resulting c(s) distributions are shown, in which the peaks for the observed s
values of the monomer, dimer and tetramer are denoted by M, D, and T respectively. The concentrations are shown in each panel, highlighted according to their
colors in the c(s) distributions. (A) For SCR-19/20, the c(s) analyses showed a single monomeric peak. For SCR-18/20, the c(s) analyses showed mostly monomer
and some dimer. For SCR-16/20, the c(s) analyses showed two partly resolved peaks corresponding to monomer and dimer. (B) For SCR-16/18H, the c(s)
distribution on the left shows interference optics while the right shows absorbance optics. The two peaks M and D correspond to monomeric and dimeric SCR-16/
18H. (C) For SCR-17/18H, the two peaks M and D correspond to monomer and dimer. (D) For SCR-18H, the two peaks M and D correspond to monomer and
dimer. (E) For SCR-17H, the two peaks M and D correspond to monomer and dimer.January 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor Hformation. The f/fo ratio was 1.3 for the monomer and 1.4 for the
dimer, indicating that the protein became slightly more
elongated upon dimer formation (Table 1).
(v) For SCR-17/18H, the interference and absorbance data
showed monomer and dimer peaks (Figure 3C). The s20,w values
were 2.1 S to 2.5 S for the monomer and 3.4 S to 3.6 S for the
dimer (Figure 4A). The experimental molecular masses were 21–
24 kDa for the monomer and 44–49 kDa for the dimer, in good
agreement with a sequence-calculated monomer mass of 22 kDa.Frontiers in Immunology | www.frontiersin.org 8SCR-17/18H existed as 80% dimer (Figure 4B), giving a KD for
SCR-17/18H dimer formation of 3 ± 1 µM. The f/f0 ratio was 1.3
for both the monomer and dimer, showing that both were
relatively compact in their structures.
(vi) SCR-18H also showed two peaks in the c(s) distribution
(Figure 3D). The first peak showed s20,w values of 2.2–2.5 S and
the second peak showed s20,w values of 3.5–4.0 S. The two peaks
were each approximately 50% in size (Figure 4B), giving a KD
value for SCR-18H dimer formation of 37 ± 27 µM. The c(M)TABLE 1 | AUC and SAXS parameters for the seven SCR fragments in 137 mM and 50 mM NaCl.
Domains s020,w (S) s
0
20,w (S) f/f0 f/f0 RG (nm)
a RG/RO RG (nm)
a RG/RO L (nm) L (nm)
137 mM 50 mM 137 mM 50 mM 137 mM 137 mM 50 mM 50 mM 137 mM 50 mM
SCR-19/20 monomer 1.64 1.8 1.1 1.04 2.4 ± 0.09 1.7 2.2 ± 0.1 1.6 8.2 ± 0.4 8.2 ± 0.4
SCR-18/20 monomer 2.4 2.4 1.1 1.1 3.2 ± 0.06 2 3.4 ± 0.1 2 12.2 ± 0.6 11.7 ± 0.6
SCR-18/20 dimer 2.9 2.9 1.6 1.6 3.62 ± 0.03 2.2 3.6 ± 0.03 2.2 12.7 ± 0.3 12.3 ± 0.6
SCR-16/20 monomer 2.59 3.1 1.5 1.3 4.7 ± 0.06 2.4 4.8 ± 0.1 2.5 16.8 ± 0.8 17.5 ± 0.8
SCR-16/20 dimer 3.63 4.2 1.7 1.5 6 ± 0.1 3.1 6.1 ± 0.1 3.2 21 ± 1 24 ± 0.2
SCR-16/18H monomer 2.47 2.2 1.3 1.5 4.7 ± 0.04 2.7 4.4 ± 0.1 2.5 17 ± 0.8 15.5 ± 0.8
SCR-16/18H dimer 3.68 3.5 1.4 1.5 4.7 ± 0.06 2.7 4.4 ± 0.01 2.5 17 ± 0.5 15.9 ± 0.8
SCR-17/18H monomer 2.49 2.2 1.3 1.3 2.7 ± 0.2 1.7 2.7 ± 0.1 1.4 9 ± 0.5 9.7 ± 0.5
SCR-17/18H dimer 3.77 3.8 1.3 1.3 2.8 ± 0.01 1.7 2.8 ± 0.01 1.4 10.2 ± 0.5 9.7 ± 0.2
SCR-18H monomer 2.51 2.32 1.2 1.3 2.2 ± 0.03 1.4 2.2 ± 0.03 1.5 8 ± 0.4 7.9 ± 0.4
SCR-18H dimer 3.49 3.69 1.3 1.3 2.2 ± 0.01 1.4 2.2 ± 0.02 1.5 8 ± 0.1 7.9 ± 0.3
SCR-17H monomer 1.56 1.82 1.2 1.7 3.5 ± 0.03 2.2 3.2 ± 0.01 2 12 ± 0.6 11.9 ± 0.6
SCR-17H dimer 2.37 2.86 1.6 1.6 3.4 ± 0.01 2.2 3.2 ± 0.1 2 12 ± 0.1 11 ± 0.6January 2021 | Volume 11 | ArtiaFor the SAXS results, the monomer is taken as the value recorded at the lowest concentration (i.e. lowest dimer percentage) and the dimer is taken as the highest concentration (i.e. the
highest dimer percentage).A
B
FIGURE 4 | Concentration-dependence of the sedimentation data for each of the SCR fragments. (A) The sedimentation coefficients s20,w corrected for buffer
density and temperature for the monomer (M) is denoted by filled circles, and for the dimer (D) with filled squares. Statistical error bars are shown where visible.
(B) The relative percentage of monomer and dimer present in the c(s) analyses. The inset to the right summarizes the relative percentages of monomer (M) and dimer
(D) from the AUC analyses. SCR-17 and SCR-18 are highlighted in yellow as the dimer site.cle 601895
Dunne et al. C-Terminal Dimers of Complement Factor Hanalyses gave molecular masses of 20–31 kDa for the first peak
and 37–57 kDa for the second peak. Both values were double
those expected from the sequence-calculated mass of 11 kDa for
the monomer, thus it was not clear if the two peaks corresponded
to monomer-dimer or dimer-tetramer. It is possible that the
relatively large glycan chain on SCR-18H may affect the
sedimentation results. Nonetheless the f/f0 ratio was calculated
to be similar at 1.2 for the first peak and 1.3 for the second peak
assuming that these corresponded to monomer and dimer,
showing that both were relatively compact in their structures.
(vii) For SCR-17H, two peaks were also evident in the c(s)
distribution (Figure 3E). The first peak showed s20,w values of
1.5–1.9 S and the second peak showed s20,w values of 2.4–2.7 S.
SCR-17H exists as 80% dimer (Figure 4B), from which the KD
value for dimer formation was 5 ± 4 µM. The c(M) analyses gave
molecular masses of 17–23 kDa for the first peak and 30–41 kDa
for the second peak. As found with SCR-18H, both values were
double those expected from the sequence-calculated mass of 10
kDa for the monomer, thus it was not clear if the two peaks
corresponded to monomer-dimer or dimer–tetramer.
Nonetheless the s20,w values were in the expected range for
monomeric and dimeric SCR-17H. The f/f0 ratios were
calculated for monomeric and dimeric SCR-17H to be 1.14 for
the monomer and 1.6 for the dimer, indicating some elongation
upon dimer formation.
With the exception of SCR-19/20 which was monomeric, the
other six SCR fragments each showed two distinct c(s) peaks
corresponding to monomer and dimer. The strongest
dimerization with KD values in the range of 3-6 µM was
observed for the three smaller fragments when SCR-17H was
present (inset, Figure 4B), thus it was confirmed that SCR-17H
comprised the main C-terminal CFH dimer site. SCR-18H alone
also showed self-dimerization. The three larger fragments
showed weaker dimer formation with KD values of 31 µM, 37
µM and 590 µM.
AUC of the Seven CFH Fragments
in 50 mM NaCl
The same AUC analysis was carried out on each of the seven SCR
fragments, but in low salt buffers containing 50 mM NaCl in
order to act as a control for the above analyses that used 137 mM
NaCl buffers. Low salt buffer will promote stronger interactions
between charged groups if present. Interference and absorbance
optics were used for all the SCR fragments except for SCR-16/20
when only interference optics were used (data not shown) (39).
(i) The c(s) distribution for SCR-19/20 again showed only one
peak for monomer with an s20,w value of 1.8 S and 1.7 S
between 0.5–2.0 mg/ml (Table 1).
(ii) The c(s) distribution for SCR-18/20 also again showed a
major monomer peak in the c(s) distribution with an s20,w
value of 2.2–2.3 S, together with a small shoulder peak at
concentrations above 1 mg/ml with a s20,w value of 2.9 S.
Because the monomer accounted for 80% of the protein, the
KD value for dimer formation was estimated at 180 ± 130 µM
(Table 1).Frontiers in Immunology | www.frontiersin.org 9(iii) SCR-16/20 again showed two partially resolved peaks
corresponding to monomer and dimer. The monomer
showed an s20,w value of 2.8–3.1 S for 0.5–2 mg/ml while
the dimer showed an s20,w value of 4.2 S. The percentage of
dimer increased with concentration from 11% to 30%, leading
to a KD value for dimer formation of 90 ± 20 µM (Table 1).
(iv) SCR-16/18H showed a monomer peak in the c(s) plot with
an s20,w value of 2.2 S and a dimer peak with an s20,w value of
3.3–3.5 S. Monomer and dimer comprised 50% each, and the
KD value for dimer formation was of the order 10 µM.
(v) SCR-17/18H showed a smaller monomer c(s) peak at a s20,w
value of 2.2 S and a larger dimer peak at 3.5–3.8 S. The
percentage of dimer was 80% and this corresponded to a KD
value for dimer formation of 2 ± 1 µM.
(vi) SCR-18H exhibited a larger monomer c(s) peak at an s20,w
value of 2.3 S and a smaller dimer peak at an s20,w value of 3.7
S. As for the 137 mM NaCl c(s) analysis, the s20, w and mass
values were larger than expected for a 10 kDa protein. The
percentage of monomer was 60% and the KD value for dimer
formation was of the order of 60 µM.
(vii) SCR-17H showed a smaller monomer c(s) peak at an s20,w
value of 1.5–1.8 S, and a larger dimer peak at an s20,w value of
2.5–2.8 S, with 80% dimer. The KD value for SCR-17H dimer
formation was calculated to be 5 ± 3 µM. The s20,w and mass
values were larger than expected for a 10 kDa protein.
Overall, the c(s) results for 50 mM NaCl buffer agreed with the c
(s) results from the 137 mMNaCl buffer study above. The KD values
were similar in 50 mMNaCl buffer when compared to those for 137
mM NaCl buffer. Importantly, it was deduced that electrostatic
interactions were not significant in CFH dimer formation. SCR-17H
was again identified as the dimer site because the three smaller
fragments with this SCR-17 domain showed the lowest (strongest
binding)KD values in a range of 2-10 µM. In contrast the three other
KD values were 60, 90 and 180 µM.
SAXS Results for the Seven CFH
Fragments in 137 mM NaCl
SAXS yields size and shape information on macromolecules in
solution (40). SAXS data with good signal to noise was obtained
for the seven SCR fragments in 137 mM NaCl buffer. Guinier
analysis were carried out on the subtracted curves to calculate the
radius of gyration RGwhich is a measure of the overall elongation
of the molecule (Figure 5A) and the RG of the cross section (RXS)
(Figure 5B). Successful linear Guinier analyses for each of the
SCR fragments were carried out within satisfactory fit limits of
the Q.RG and Q.RXS values, namely 0.6–1.2 and 0.4–1.0
respectively. The RG/RO ratio compares the elongation of the
protein with respect to a sphere, where RO is the RG of a perfect
sphere with the same volume as the hydrated protein. Typical
globular proteins have a RG/RO ratio of 1.28 (41). Solution
scattering represents an average of the species present in the
sample, and monomer and dimer could not be distinguished as
such. Nonetheless scattering provides an independent monitor of
the extent of SCR dimerization to complement the AUC data.January 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor HFor the three non-His-tagged fragments SCR-19/20, SCR-18/
20, and SCR-16/20, Guinier analyses were carried out:
(i) For SCR-19/20, the RG value was 2.4 ± 0.1 nm and the RG/RO
ratio was 1.7 indicating that it was elongated with respect to a
globular protein of the same size. SCR-19/20 had an RXS value
of 0.86 ± 0.04 nm. Neither the RG nor the RXS changed
significantly with respect to concentration as expected for the
monomeric SCR-19/20 fragment (Figures 6A, B).
(ii) For SCR-18/20 the RG value increased with concentration
from 3.2 ± 0.1 nm to 3.6 ± 0.03 nm (Figure 6A). The RG/RO
ratio increased from 2.0 to 2.2 which showed that SCR-18/20
had an elongated shape which became further elongated upon
dimer formation. The RXS value for SCR-18/20 increased
from 0.9 ± 0.04 nm to 1.2 ± 0.1 nm (Figure 6B).
(iii) For SCR-16/20, the RG value increased from 4.7 ± 0.1 nm to
6.0 ± 0.1 nm (Figure 6A). The RG/RO ratio increased from 2.4Frontiers in Immunology | www.frontiersin.org 10to 3.1, with SCR-16/20 becoming more elongated upon dimer
formation. The RXS value increased with concentration from
1.6 ± 0.08 nm to 2.04 ± 0.1 nm (Figure 6B); the increase in
RXS compared to that of SCR-19/20 showed that dimerization
occurred by a side-to-side association of the five SCR
domains.
For the four His-tagged SCR fragments, Guinier analyses
showed that the RG values did not change significantly with
concentration (Figures 6A, B).
(iv) SCR-16/18H had an RG value of 4.7 ± 0.1 nm and an RG/RO
ratio of 2.7. The RXS value for SCR-16/18H was 1.6 ± 0.08 nm.
These values resembled those for SCR-16/20.
(v) SCR-17/18H had an RG value of 2.8 ± 0.1 nm and an RG/RO
ratio of 1.7. SCR-17/18H had an RXS value which increased at
higher concentrations from 0.51 ± 0.03 nm to 0.73 ± 0.04 nmA B
FIGURE 5 | Guinier RG and RXS analyses for each of the seven SCR fragments. The filled circles represent the experimental X-ray data points used to determine the
RG and RXS values. Their values were measured within the satisfactory Q.RG and Q.RXS ranges shown in each panel. (A) The SCR fragment concentrations in 137
mM NaCl buffer are shown in the panels, where the colors correspond to the indicated concentrations. The filled circles correspond to the I(Q) values used to
determine each RG value. The Q ranges used for the RG fits were 0.24–0.44 nm
−1 for SCR-19/20, 0.14–0.3 nm−1 for SCR-18/20, 0.10–0.22 nm−1 for SCR-16/20
monomer and SCR-16/18H, 0.10–0.14 nm−1 for the SCR-16/20 dimer, 0.20–0.44 nm−1 for SCR-17/18H, 0.17–0.45 nm−1 for SCR-18H and 0.14–0.28 nm−1 for
SCR-17H. (B) The corresponding RXS analyses for the seven SCR fragments are shown, where the Q ranges used for the RXS fits were 0.55–1.02 nm
−1 for SCR-19/
20, 0.39–0.79 nm−1 for SCR-18/20, 0.28–0.6 nm−1 for the SCR-16/20 monomer, 0.28–0.50 nm-1 for the SCR-16/20 dimer, 0.22–0.49 nm-1 for the SCR-16/18H
monomer, 0.35–0.60 nm-1 for the SCR-16/18H dimer, 0.53–1.09 nm−1 for SCR-17/18H, 0.45–0.88 nm−1 for SCR-18H and 0.7–1.19 nm−1 for SCR-17H.January 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor H(Figure 6B). Its RG value was larger than that of SCR-19/20,
this being attributed to its larger size and glycosylation.
(vi) SCR-18H had an RG value of 2.3 ± 0.03 nm, an RG/RO ratio of
1.4, and an RXS value of 2.3 ± 0.1 nm. The similarity of its RG
value to that of SCR-19/20 is consistent with SCR-18H
existing as a mixture of monomer and dimer, although its
glycosylation and His-tag will complicate this interpretation.
(vii) SCR-17H had an RG value of 3.5 ± 0.02 nm, an RG/RO ratio
of 2.2, and an RXS value of 3.5 ± 0.2 nm. Its significantly larger
RG and RXS values compared to SCR-19/20 and SCR-17/18H
is attributed to its high level of dimer formation as well as its
glycosylation and His-tag. This agrees with the 80% dimer
seen in the AUC c(s) analyses.
The distance distribution function P(r) provides the
maximum dimension of the macromolecule L and the most
frequently observed interatomic distance M (Figure 7; Table 1).
As a check, the P(r) analyses were found to give RG values that
agreed well with the Guinier RG values.
(i) SCR-19/20 gave a length L of 8.2 ± 0.4 nm and an M value of
1.7 ± 0.1 nm, neither of which changed with concentration as
expected for a monomer.
(ii) SCR-18/20 gave a length L of 12.2 ± 0.6 nm and anM value of
2.7 ± 0.1 nm at high concentration. The increase in L is as
expected from the addition of an extra SCR domain of length
3.6 nm to SCR-19/20.
(iii) For SCR-16/20, the length L increased with concentration
from 16.8 ± 0.8 nm to 21 ± 1 nm. The M values also increased
from 4.0 ± 0.2 nm to 4.8 ± 0.2 nm. This indicated increases in
its dimerization with concentration, this being consistent with
the AUC data.Frontiers in Immunology | www.frontiersin.org 11(iv) SCR-16/18H gave a length L of 17 ± 0.8 nm and an M value
of 4.1 ± 0.2 nm with no observed concentration dependent
changes. The additional length when compared to SCR-18/20
indicated that the His-tag is extended in its conformation.
(v) For SCR-17/18H, its length L was between 9 ± 0.5 nm to 10.2
± 0.5 nm with M values of 1.7 ± 0.1 nm. Because these lengths
are not much greater than that for SCR-19/20, this outcome
suggested that dimerization occurred through a side-by-side
association of SCR-17/18.
(vi) SCR-18H had a length of 8 ± 0.4 nm and an M value of 2.1 ±
0.1 nm. These relatively large values are consistent with dimer
formation and the presence of glycosylation and the His-tag
in its structure.
(vii) SCR-17H had an L value of 12 ± 0.6 nm with an M value of
2.6 ± 0.1 nm. These larger values compared to SCR-18H
showed that more dimer was present in this case, as suggested
by the AUC analyses.
Overall the SAXS analyses confirmed the AUC analyses that
showed that SCR-19/20 was monomeric, and that dimerization
occurred for the other six SCR fragments. The RXS and L values
suggested that dimer formation occurred as a side-by-side
association and not as an end-to-end association.
SAXS Results for the Seven CFH
Fragments in 50 mM NaCl
Similar SAXS analyses were performed on each of the seven SCR
fragments in buffers containing 50 mM NaCl as a control to
check the effect of low salt on protein dimerization (data not
shown; Table 1) (39). The Guinier RG and RXS plots gave high
quality linear fits, as exemplified in Figure 5 for 137 mM NaCl
buffer, within the satisfactory fit limits of the Q.RG and Q.RXSA
B
FIGURE 6 | Concentration-dependence of the RG and RXS value of the seven SCR fragments. (A) The X-ray RG values are shown, where the lines denote the mean
value. (B) The X-ray RXS values are shown, where the lines denote the mean value.January 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor Hvalues as above. For the seven SCR fragments, similar RG and RXS
results to those in 137 mM NaCl were obtained (Table 1). The
distance distribution P(r) curves for each of the SCR domains
were likewise calculated for comparison with those obtained for
137 mM NaCl (not shown). Again, little difference in the lengthsFrontiers in Immunology | www.frontiersin.org 12L was observed between 137 mM and 50 mMNaCl (Table 1). As
for the AUC results, lowering the ionic strength of the buffer did
not significantly alter the calculated SAXS parameters for the
SCR fragments. This confirmed the above AUC results that
electrostatic interactions were not significant in dimer formation.FIGURE 7 | Distance distribution function P(r) analyses for each of the seven SCR fragments. The arrow under each peak represents M, the most frequent distance
within the protein, and L represents the maximum observed dimension of the SCR fragment.January 2021 | Volume 11 | Article 601895
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Seven CFH Fragments
Atomistic scattering modelling reproduces the SAXS scattering
curves of a macromolecule by recourse to physically-realistic
molecular models created from Monte Carlo and molecular
dynamics simulations (42). To model the seven C-terminal
SCR fragments in this study, we used the recently published
scattering model of full-length CFH to create molecular
structures for the seven individual CFH fragments (6). That
study generated 29,715 physically-realistic conformationally-
randomized structures for CFH, from which the 100 best-fit
structures to the scattering curve of full-length CFH were
identified, as well as a single best-fit median CFH structure.
Starting from the best fit model of that study, the seven SCRFrontiers in Immunology | www.frontiersin.org 13fragments were created by edits of the full-length CFH structure.
The C-terminal His-tags were modelled onto four of these
fragments (Supplementary Figure 1). For the three non-His-
tagged models, additional molecular structures for these
fragments were extracted from the 100 best-fit CFH structures
in order to assess the variability of the calculations between
different structures in that set.
The scattering curve fits (Figure 8) confirmed the above AUC
and SAXS results on the dimerization of the CFH fragments.
Because the SAXS data represent an average of the species
present in solution, the fits do not distinguish monomer and
dimer, but rather the deviation of the fits from an assumed
monomer structure. The modelling did not consider directly the





FIGURE 8 | Scattering curve fits for the atomistic models for each of the SCR fragments. (A–G) For each of the seven SCR fragments, the panels compare the
experimental X-ray scattering and theoretical scattering curves. The theoretical curves are shown in black, and the experimental curves are shown in color to
correspond to the different concentrations shown in the same panel. In (A–C), curves from the 100 best-fit models are shown in brown.January 2021 | Volume 11 | Article 601895
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goodness-of-fit R-factor for each fragment model when
compared with up to three different experimental curves, and
by assuming that the monomer models would give good curve
fits if the solution structure was monomeric, it was possible to
assess the extent to which dimerization had perturbed the curve
fits. As a bench mark, SCR-19/20 should give the best fits as this
was determined to be monomeric by AUC and SAXS. The
reasonable visual fits (Figure 8A) and R-factors of 14–17%
(Table 2) indicated the type of fits that were obtained
Relatively low amounts of dimer were seen for SCR-18/20 byFrontiers in Immunology | www.frontiersin.org 14AUC (Figure 1B) and SAXS; the visual fits (Figure 8B) and R-
factors of 15% (Table 2) corroborated the relatively low amounts
of dimer present for this fragment. For SCR-16/20, the presence
of 40% dimers by AUC were confirmed by increases in the R-
factors from 40 up to 64% as the concentration (and proportion
of dimer) increased. For the four His-tagged fragments, while
SCR-18H showed good agreements in the curve fits, the fits for
SCR-16/18H, SCR-17/18H, and SCR-17H were poorer and gave
R-factors as high as 68%. Taken together, the R-factors indicated
that the primary location of CFH dimerization was again seen to
be SCR-17, with some contribution from SCR-18.FIGURE 9 | The seven atomistic models for the SCR fragments. The structures of the C-terminal fragments of CFH used for the curve fits are shown. The individual
SCR domains are labelled. Yellow surfaces represent the single glycan chains located on each of SCR-17 and SCR-18. The C-terminal tag is shown as a purple surface.TABLE 2 | The modelling of the AUC s020,w values and the best curve fit R-factors for the SCR fragments.
Fragment s020,w (S) experimental s
0
20,w (S) modelled R-factor 1.0 mg/ml 1.5 mg/ml 2.0 mg/ml 3.5 mg/ml
SCR-19/20 1.4 1.4 14.4% 15.0% 17.1%
SCR-18/20 2.4 1.9 14.5% 15.2%
SCR-16/20 2.7 2.7 40.2% 53.9% 64.4%
SCR-16/18H 2.3 1.9 51.2% 51.0% 49.5%
SCR-17/18H 2.3 1.8 22.5% 23.0%
SCR-18H 2.4 1.1 6.4% 5.8%
SCR-17H 1.7 1.2 68.0% 66.0% 65.2%January 2021 | Volume 11 | ArtThe R-factor was calculated using the R-factor metric in the SASSIE package. For each SCR fragment, the R-factor was calculated at each of the concentrations in use from 1.0 mg/ml to
3.5 mg/ml.icle 601895
Dunne et al. C-Terminal Dimers of Complement Factor HAs another test of the scattering modelling, the s020,w values for
the models of the sevenmonomeric CFH fragments (Figure 9) were
calculated using HYDROPRO (Table 2). Given that the mean
difference between the modelled and experimental values should
be ± 0.21 S for related macromolecules (43), excellent agreements
were obtained for monomeric SCR-19/20 and SCR-16/20, but less
so for the SCR-18/20 monomer where the model appeared too
elongated compared to the experimental value. For the four His-
tagged fragments in Table 2, the calculations suggested that the
models were too elongated compared to the experimental values.
The simplest explanation of this is that the His-tag tails and glycans
were extended in the models as shown in Figure 9. While these
calculations corroborated the modelling for the monomeric
fragments, overall the agreement was only qualitative.
Further experimental AUC analyses were made using the f/f0
ratio which monitors the extent of how much the frictional
coefficient of the glycoprotein deviates from that for a sphere of
the same volume. The experimental f/f0 ratio of 1.1 for
monomeric SCR-19/20 defined a benchmark for two linearly-
arranged SCR domains (Table 1; Figure 9). SCR-18/20 also
showed an experimentally low f/f0 ratio of 1.1 (Table 1). As
deduced from the f/f0 ratios of 1.3–1.5 (Table 1), the three SCR-
16/20, SCR-16/18H, and SCR-17/18H monomers have similar
but more elongated shapes. The similarity of the f/f0 ratios of 1.3
for SCR-16/18H and SCR-17/18H indicated that the three-
domain SCR-16/18H structure possessed a bent back solution
structure of similar elongation to the two-domain SCR-17/18H
structure. The sedimentation properties of the single SCR-17H
and SCR-18H domains are likely to be perturbed by their
relatively large glycan and His-tag groups, thus no further
interpretation of their values was made here. It was however
interesting that the f/f0 ratios for the dimers of SCR-16/20, SCR-
18/20, SCR-16/18H, SCR-17H, and SCR-18H showed that they
became more elongated in their dimers compared to their
monomers (Table 1). However, that for SCR-17/18H was
unchanged in its dimer, suggesting that this was formed by a
side-by-side interaction.
Previously SCR dimers have been seen in the crystal structure
of FHR1 SCR-1/2, in which two copies of SCR-1/2 formed an anti-
parallel dimer. This anti-parallel dimer structure was used to test
whether the FH SCR-17/18 dimer could be formed from protein-
protein contacts in the same way as the dimer interface seen in the
FHR1 SCR-1/2 structure. Using the crystal structure of FHR1 as a
template (PDB code 3ZD2), a model of the SCR17/18 dimer
interface was constructed. A multiple sequence alignment between
FHR1-SCR1/2 and SCR-17/18 of CFH gave a relatively low
sequence homology of 41% between the two fragments. When
CFH SCR-17 was aligned with FHR1 SCR-1, and SCR-18 was
aligned with SCR-2 through their b4-strands, the resulting SCR-
17/18 dimer model showed ill-fitting gaps at their interface. These
observations argued against an antiparallel SCR arrangement for
the C-terminal CFH dimer at SCR-17 and SCR-18. Accordingly,
because each of SCR-17H and SCR-18H form dimers on their
own (Figure 4B), it was concluded that a parallel arrangement of
the SCR-17/18 domains is found in the SCR-17/18 dimer detected
by AUC analysis.Frontiers in Immunology | www.frontiersin.org 15DISCUSSION
Full length CFH forms weak dimers with an estimated range of
4–15% dimer present at typical CFH serum concentrations of
0.8–3.6 µM (0.116–0.562 mg/ml) (44). The dissociation
constants KD values for dimer formation ranged between 8–28
µM (45), thus CFH dimers are expected to co-exist with CFH
monomers at physiological conditions in serum. The CFH self-
association sites have previously been shown to be located in the
SCR-6/8 and SCR-16/20 regions (12, 13, 46). Up to now, the
more precise location of the SCR-16/20 dimerization site was not
known, and this identification was addressed here. It was
unlikely that the dimerization site would reside on either SCR-
19 or SCR-20, because of the functional interaction of SCR-19
and SCR-20 with the C3d fragment of complement C3b and
sialic acid as reported in crystal structures (47–51) (PDB codes
3OXU, 2XQW, 4ONT, 4ZH1, 5NBQ). This was confirmed in
this study by showing that SCR-19/20 remained monomeric
using a combination of AUC and SAXS experiments in 137 mM
and 50 mM NaCl buffers, coupled with molecular simulations of
the AUC and SAXS data based on the coordinates of our recent
full-length CFH model (6). In contrast, using the same strategy,
six other fragments containing SCR-17 and SCR-18 showed
various degrees of dimer formation. The strongest dimer
formation with KD values of 3-6 µM was observed for SCR-
17H, SCR-17/18H, and SCR-16/18H, in which SCR-17H showed
higher dimer formation than SCR-18H. These data indicated
that SCR-17H comprised the main C-terminal CFH dimer site.
The presence of additional or alternative SCR domains as found
in the SCR-16/20, SCR-18/20H, and SCR-18H fragments
resulted in weaker dimer formation, indicating that SCR-18H
made some contribution to this. Since full-length CFH showed
extents of dimerization of 4–15% (12), while the smallest
fragments showed dimerization of up to 80% (Figure 4B), the
reduced dimer formation for larger CFH molecules is attributed
to steric effects caused by the larger sizes of the CFH proteins in
question. Their larger sizes are presumed to inhibit dimer
formation. It should also be noted that the present study used
a non-His tagged form of SCR-16/20, while our previous study
used a His-tagged variant (13). Both studies gave similar AUC
results, indicating that the presence of the His-tag made no
difference on its dimerization.
The major complement regulator CFH functions to protect
host cells from destruction through its C-terminal binding to
C3b and anionic host cell surfaces mediated by the SCR-19 and
SCR-20 domains. Our novel report of a CFH dimer site in SCR-
17/18 may provide CFH with a functional mechanism through
which CFH can become more concentrated on host surfaces
during an inflammatory response. The SCR-17/18 dimer site is
seen to be independent of the crystallographic-observed C3dg
and anionic oligosaccharide binding sites on SCR-19/20 in the C-
terminal region of CFH (Figure 10). Despite the presence of
multiple binding sites for C3dg and polyanions, the schematic
view of C3dg binding to SCR-19 and the dimer formation at
SCR-17/18 in Figure 10 indicated that dimer formation will still
proceed when a single CFH molecule is bound to a host cellJanuary 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor Hsurface through either cell-bound C3dg or polyanions. The single
surface-bound CFH molecule will allow an additional CFH
molecule to be recruited through a SCR-17/18 dimerization
event to protect further the host surface under inflammatory
conditions of excessive C3b deposition. In reflection of this
topology, the 37 genetic variants throughout SCR-20 reported
so far that lead to aHUS disease are comparatively abundant in
CFH (Figures 1B, C) (17), indicating the importance of C-
terminal CFH binding to host cell surfaces. The fewer variants
reported to date for SCR-16 (six), SCR-17 (four), SCR-18 (ten)
and SCR-19 (seven) might involve incorrect folding of the C-
terminal domains if they alter any of the highly conserved Cys or
Trp residues, or a reduction in dimer formation or C3dg binding
(19). Visual inspection of the locations of these variants in the
SCR-16/20 model (Figures 1B, 10) showed little further insight.
Further experimental studies will identify the effect of the aHUS
variants in SCR-17/18 on dimer formation in order to clarify the
importance of C-terminal dimerization in CFH. Of interest was
that no significant differences in dimer formation were observedFrontiers in Immunology | www.frontiersin.org 16between the 137 mM and 50 mM NaCl buffers, suggesting that
electrostatic interactions were not significant in SCR-16/20
dimer formation (Table 1).
Besides CFH itself, another distinct SCR dimer has been
observed in other members of the CFH gene family. The FHR
proteins (52) including FHR1 with five SCR domains, FHR2 with
four SCR domains, and FHR5 with nine SCR domains exist as
dimers formed by an antiparallel pairing of their SCR-1/2 N-
terminal domains, as opposed to the parallel pairing proposed
for SCR-17/18. FHR dimerization confers avidity for their
binding to complement activation fragments bound to host cell
surfaces, and enables these FHR proteins to compete with CFH
for binding (36). For FHR5, we showed that the antiparallel
FHR5 dimer with 18 SCR domains has a compact domain
structure that can bind bivalently to C3b when this is bound to
host cells at a high enough surface density (53). However,
sequence alignments between SCR-1/2 of FHR1 and SCR-17/
18 of CFH showed that the three FHR1 residues (Tyr 34, Ser 36,
and Tyr 39) essential for FHR1 dimer formation were notA
B
FIGURE 10 | Putative dimer of SCR-16/20 to show the crystallographic-observed complex between SCR-19/20 and C3dg. Molecular views of the SCR-16/20
fragment model (grey/green) determined from this study are shown as ribbons and surfaces to show how this binds to its ligand C3dg (blue) on the SCR-19 domain.
To generate this complex, the SCR-16/20 model was superimposed onto the crystal structure of the SCR-19/20 and C3dg co-complex (PDB code: 5NBQ). The
yellow surfaces show the two glycan chains located at each of SCR-17 and SCR-18. (A) The side-on view shows C3dg attached to the host cell surface (thick blue
line) through its thioester group, as well as showing how SCR-17 and SCR-18 form a dimeric interface with another SCR-16/20 molecule (Figure 4B). (B) The same
structure is viewed from the top to show the five individual SCR domains in each monomer of the SCR-16/20 dimer. This view corresponds to a 90° rotation about a
horizontal axis compared to that in (A) The reminder of the CFH structure SCR-1/15 is denoted by a dashed green line.January 2021 | Volume 11 | Article 601895
Dunne et al. C-Terminal Dimers of Complement Factor Hconserved in SCR-17/18 which contains Thr residues at the
equivalent positions. This difference makes it unlikely that
SCR-1/2 of FHR1 would be a good model for the CFH dimer
structure at SCR-17/18.
Our multidisciplinary approach to analyse the solution
properties of the seven C-terminal SCR fragments showed
consistent results from both the AUC and SAXS data sets. The
main results showed that SCR-19/20 is monomeric, and that
SCR-16/20 and SCR-18/20 became more elongated with dimer
formation (Table 1). For the remaining fragments, the AUC data
showed a range of dimer formation had taken place, although
information from SAXS about shape or size changes associated
with dimer formation was more limited because the scattering
curves correspond to mixtures of monomer and dimer, and the
AUC shape data were of limited precision. Nonetheless there was
sufficient information in the datasets to indicate that SCR-17 and
SCR-18 comprised the main dimerization site in the C-terminal
region of CFH. Both the AUC and SAXS data sets were accessible
to molecular modelling in order to clarify the significance of the
experimental data sets. The application of modelling here
confirmed that the largest deviations from the SAXS curve fits
on the assumption of SCRmonomers correlated with the greatest
amount of dimer formation (Table 2), as well as showing that the
CFH monomer models accounted well for the AUC s20,w values.
In this analysis, the AUC and SAXS modelling outcomes
extended our understanding of the proportions of monomer
and dimer deduced from AUC (Figure 4B). The molecular
modelling also provided a new functional explanation for the
formation of SCR-17/18 dimers, and insight into why aHUS
disease-associated genetic variants occur along the length of
SCR-16/20 and not just in SCR-20 (Figure 10).AUTHOR’S NOTE
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